Navigation Links
NexGenix Pharmaceuticals to Present at Two Industry Conferences: Rodman & Renshaw 11th Annual Healthcare Conference and Life Sciences Summit 2009
Date:9/10/2009

NEW YORK, Sept. 10 /PRNewswire/ -- NexGenix Pharmaceuticals Holdings, Inc. (Privately Held) today announced that Chief Executive Officer Dr. Allan E. Rubenstein will be presenting at two industry conferences during the month of September. The first presentation will take place on September 11th, 2009 at 11:40am as part of the Rodman & Renshaw 11th Annual Healthcare Conference in New York, New York. The second presentation will take place on September 23, 2009 at 4:15pm as part of the Life Sciences Summit 2009 in Hauppauge, New York. All times are local time.

Dr. Rubenstein will be presenting an overview of the Company's preclinical results related to its series of heat shock protein 90 (Hsp90) inhibitors, speak about the Company's forward drug development strategy and timeline, and present high-level fiscal results for 2009.

About NexGenix: NexGenix Pharmaceuticals Holdings, Inc. is a privately-held biotechnology company based in New York City. The Company's portfolio consists of a series of Hsp90 inhibitors, a novel target therapy for oncology and neurodegenerative disorders, which has attracted an enormous amount of development interest in the past several years. The Company's proprietary Hsp90 screening platform has already generated over 300 potential compounds. From this group, three lead drug candidates have been identified on the basis of superior efficacy, safety, and the ability to cross the blood brain barrier. The product profiles lend themselves to address diseases such as glioblastoma (or "glioma", commonly known as malignant brain tumor) and other cancers, as well as neurodegenerative disorders including the motor neuron disease ALS (Lou Gehrig's disease) and Parkinson's disease. Each of these indications represents a world-wide market of at least $1B/year. In addition, the Company has a clinical stage intralesional treatment for dermal neurofibromas, the most co
'/>"/>

SOURCE NexGenix Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect
2. NexGenix Pharmaceuticals Enters into Exclusive World-wide License to Develop Novel Hsp90 Inhibitors
3. ISTA Pharmaceuticals to Present at NewsMakers in the Biotech Industry Conference
4. Access Pharmaceuticals Provides Update on ProLindac(TM)Clinical Development Plan
5. Mpex Pharmaceuticals Announces Positive Phase 2b Clinical Trial Results with Aeroquin(R) (MP-376) Treatment in Cystic Fibrosis Patients
6. Esperance Pharmaceuticals Announces Initiation of Clinical Studies of its Novel Membrane-disrupting Agent, EP-100, in Patients with Cancer
7. Rib-X Pharmaceuticals to Present at the 49th ICAAC
8. Cadence Pharmaceuticals to Present at Two Investment Conferences During the Month of September 2009
9. Dont Wait to Innovate: Future Pharmaceuticals Magazine Releases Its Issue on Innovation in IT, Cell-Based Therapy and Supply Chains
10. EnVivo Pharmaceuticals Names Stephen DiPalma Chief Financial Officer
11. Oramed Pharmaceuticals Commences Human Clinical Trials of an Oral GLP-1 Analog
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 27, 2015  CASI Pharmaceuticals, Inc. (Nasdaq: CASI ... and commercialization of innovative therapeutics addressing cancer and other ... commercial focus on China , today ... ended December 31, 2014.  The Company ... per share, for the three months ended December 31, ...
(Date:3/26/2015)... CA (PRWEB) March 26, 2015 PRC ... (CRO), announced today several management and executive appointments effective ... Chief Financial Officer (CFO) and member of the Board ... of Business Operations, and Sue Dowden will assume the ... co-founder and current Chief Operations Officer (COO), has been ...
(Date:3/26/2015)... 26, 2015  BioNano Genomics, Inc., the leader in ... as chief commercial officer. Salyer has more than ... teams in life sciences. At BioNano, Salyer will oversee ... genome-mapping platform to assemble a comprehensive view of complex ... date, 32 institutions located in the United ...
(Date:3/26/2015)... 26, 2015 PAREXEL International Corporation ... clinical research organization , announced today that ... to acquire all of the business assets of ... provider of specialized pharmacovigilance services, based in ... detection, assessment, monitoring, and prevention of adverse ...
Breaking Biology Technology:CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 3CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 4CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 5CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 6PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 2PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 3BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 2BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 3PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 3PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 4
... ( Medical Device and Diagnostic Industry ), ... latest news , information, and in-depth analysis, wins a ... Dental & Related Services/Trade Category for their December 2011 issue. ... finalist for the Best Cover (Circ under 50,000)/Trade. (Photo: ...
... May 3, 2012 , Point-of-Care Diagnostics ... program funded by Bill & Melinda Gates Foundation and Grand ... technologies will aid effort to create a low-cost portable testing ... Development expected to be completed by 2014, ...
... The Muscular Dystrophy Association announced today that it has ... company, to develop and test a "dissociative glucocorticoid" as ... . (Logo: http://photos.prnewswire.com/prnh/20120424/DC93207LOGO ) ... of Health Therapeutics for Rare and Neglected Diseases (TRND) ...
Cached Biology Technology:MD+DI, the Global MedTech Industry Authority, Wins a 2012 Maggie for Best Cover in the Medical, Dental & Related Services/Trade Category 2QIAGEN Joins Grand Challenges in Global Health Initiative to Bring Advanced Point-of-Care Diagnostics to World's Poorest Countries 2QIAGEN Joins Grand Challenges in Global Health Initiative to Bring Advanced Point-of-Care Diagnostics to World's Poorest Countries 3QIAGEN Joins Grand Challenges in Global Health Initiative to Bring Advanced Point-of-Care Diagnostics to World's Poorest Countries 4QIAGEN Joins Grand Challenges in Global Health Initiative to Bring Advanced Point-of-Care Diagnostics to World's Poorest Countries 5MDA Supports Development of 'Dissociative Glucocorticoid' for DMD 2MDA Supports Development of 'Dissociative Glucocorticoid' for DMD 3
(Date:3/11/2015)... , Mar. 11, 2015 Research and Markets ... the "Access Control Market by Product, Application & ... report to their offering. , This ... to reach $10.4 billion by 2020, with an estimated ... report covers the products types such as contact cards ...
(Date:3/10/2015)... Conn. , March 10, 2015  NXT-ID, ... ("NXT-ID" or the "Company"), a biometric authentication company ... the company,s Wocket™ smart wallet has been named ... by Rethink Modern. Rethink Modern ( ... and innovative items for your home and lifestyle that have ...
(Date:3/2/2015)... March 2, 2015  Businesses have a new ... company Tharon Rankins Enterprises has announced the launch ... ultra-safe way for businesses to protect their customers, ... Beconux is a biometric transaction ... Functioning similarly to an ATM machine, the new ...
Breaking Biology News(10 mins):Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 3NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 4Personal Data Protection Company Launches New Product 2
... in the process of how the body's nervous system relays ... one neuron fires a packet of neurotransmitter across a synapse ... led by University of Illinois at Chicago biology professor Simon ... the Proceedings of the National Academy of Sciences. , "Until ...
... transplants cured the metabolic symptoms of 11 patients with ... Syrup Urine Disease (MSUD), according to a study by ... for Special Children. , All patients from the study ... with normal liver function, according to the researchers. Amino ...
... of deaths from SIDS (sudden infant death syndrome) in African ... half of those deaths result from a common genetic variation ... rhythm during times of environmental stress, a research team based ... issue of the Journal of Clinical Investigation. , Children ...
Cached Biology News:Protein receptor cools passion of 'kiss and run' nerve cells 2Pennsylvania researchers find liver transplants provide metabolic cure for rare genetic disease 2Gene variation increases SIDS risk in African Americans 2Gene variation increases SIDS risk in African Americans 3
... Avidin is chromatographically purified from egg white. ... is 15.5.The product is in 10 mM ... bovine serum albumin, 0.05% sodium azide and 50% ... FITC. The conjugate is purified by molecular ...
in vitro Translation, Accessory Products...
Request Info...
... derivatives that have mutations in both the ... genes, which greatly enhances disulfide bond formation ... expression in Origami(DE3) yielded 10-fold more active ... overall expression levels were similar (1). Origami ...
Biology Products: